<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00678834</url>
  </required_header>
  <id_info>
    <org_study_id>2005C0034</org_study_id>
    <nct_id>NCT00678834</nct_id>
  </id_info>
  <brief_title>Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol</brief_title>
  <official_title>Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chandan K Sen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carotech Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Levels of tocotrienol in human tissues following supplementation is not currently known. The
      objective of this present study is to determine the levels of this form of vitamin E in the
      human tissues such as skin, heart, lung, liver, adipose tissue, Brain and cerebrospinal fluid
      (CSF) following oral supplementation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In nature, there are eight members in the vitamin E family: a-, b-, g- and d-TCP, and a-, b-,
      g- and d-tocotrienol (TCT). Vitamin E research has developed highly asymmetrically. Out of
      the 25,000+ papers on vitamin E in the PubMed, 99% deal with tocopherols. Recent research has
      demonstrated the lack of cancer-preventive effects and potential adverse health consequences
      of tocopherol (6). As a result, more attention has been turned towards non-tocopherol forms
      of vitamin E (16). Palm oil represents a major source of natural TCT. TCT possess powerful
      neuroprotective, antioxidant, anti-cancer and cholesterol lowering properties that often
      differ from the properties of TCP (15).

      During the last five years, our and other laboratories have reported several striking
      beneficial properties of tocotrienols in experimental settings. One major concern that limits
      enthusiasm for tocotrienol for humans is the report that the vitamin E transporting protein,
      tocopherol-transport protein (TTP), has a very low affinity to transport tocotrienol. Using
      TTP-knock out mice, we have recently demonstrated that oral TCT is effectively carried to
      vital organs and that such transport can take place independent of TTP. With that background,
      the purpose of this project is to test the hypothesis that orally supplemented tocotrienol
      reaches the vital organs of humans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Levels of TCT in the Tissues of &quot;Non-healthy&quot; Subjects and in the Tissue of &quot;Healthy&quot; Subjects Following Oral Supplementation (200 mg x 2 Per Day for 4-24 Weeks)</measure>
    <time_frame>After at least 1 month of supplementation</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>End Stage Cardiac Failure</condition>
  <condition>Pulmonary Failure</condition>
  <condition>End Stage Liver Disease</condition>
  <condition>Morbid Obesity</condition>
  <condition>Recalcitrant Epilepsy Requiring Surgery</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To surgery patients, Tocotrienol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To surgery patients, Tocopherol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tocotrienol to healthy subjects - 200 mg to take orally two times a day (400 mg a day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>To surgery patients, Tocopherol capsules.</intervention_name>
    <description>200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tocotrienol to healthy subjects.</intervention_name>
    <description>200 mg to take orally two times a day (400 mg a day).</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>To surgery patients, Tocotrienol capsules.</intervention_name>
    <description>200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Aim 1 Surgical candidate with a surgery schedule date with a time period of 4-24 weeks (&lt;4
        weeks will be excluded; last dose until 24h before surgery) In Aim 1 we expect to have
        patients, with diverse co-morbidity and medication conditions.

        Patient Selection: Because of limitation in obtaining healthy human tissues (as in Aim 2),
        we plan to obtain these tissues from patients who are scheduled for the following surgeries
        for subjects in group one:

        Heart Heart Transplant Heart Failure- Biopsy taken from diseased heart Lung Lung
        Transplant, Lung-wedge/resection, Lobectomy Cancer- Tissue sample taken from removed lung
        or resected portion of lung Liver Liver Transplant, Biopsy, Resection Hepatic Malignancy-
        Biopsy taken from resected portion of liver Adipose Tissue Panniculectomy Excessive Tissue
        of the Abdomen Brain &amp; CSF Epilepsy Excised brain tissue and cerebrospinal fluid

        To ensure higher enrollment we are not controlling for age of subjects as long as the
        subjects are 21 years of age or older.

        Inclusion Criteria Aim 1:

          -  age 21 and older

          -  good health

          -  non- smoker

          -  no current medications

          -  non- pregnant or non-breastfeeding

          -  no previous use of OTC medications or other form of supplements containing vitamin-E.

        Inclusion Criteria Aim 2:

          -  age 21 - 40 years

          -  good health

          -  non- smoker

          -  no current medications

          -  non- pregnant or non-breastfeeding

          -  no previous use of OTC medications or other form of supplements containing vitamin-E.

        Exclusion Criteria Aim 1:

          -  Long-term use of OTC medications containing vitamin-E or current vitamin-E supplements

          -  Scheduled surgery date lesser than 4 weeks or greater than 24 weeks.

        Exclusion Criteria Aim 2:

          -  Over 40 or under 21 years of age

          -  Current smoker

          -  Pregnant and breastfeeding

          -  Diabetes and HIV diagnosis

          -  Immunosuppression therapy

          -  Any neurological problems

          -  Long-term use of OTC medications containing vitamin-E or current vitamin-E supplements

          -  ETOH or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chandan Sen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Patel V, Rink C, Gordillo GM, Khanna S, Gnyawali U, Roy S, Shneker B, Ganesh K, Phillips G, More JL, Sarkar A, Kirkpatrick R, Elkhammas EA, Klatte E, Miller M, Firstenberg MS, Chiocca EA, Nesaretnam K, Sen CK. Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J Nutr. 2012 Mar;142(3):513-9. doi: 10.3945/jn.111.151902. Epub 2012 Feb 1.</citation>
    <PMID>22298568</PMID>
  </results_reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2008</study_first_submitted>
  <study_first_submitted_qc>May 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2008</study_first_posted>
  <results_first_submitted>July 2, 2014</results_first_submitted>
  <results_first_submitted_qc>September 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2014</results_first_posted>
  <last_update_submitted>September 8, 2014</last_update_submitted>
  <last_update_submitted_qc>September 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Chandan K Sen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1- Surgery + Tocotrienol 200 mg</title>
          <description>Surgery Patients to take Tocotrienol capsules.: 200mg (two 100mg capsules) taken by mouth twice to total 400mg daily</description>
        </group>
        <group group_id="P2">
          <title>Arm 2- Surgery + Tocopherol 200 mg</title>
          <description>Surgery Patients to take Tocopherol capsules.: 200mg (two 100mg capsules) taken by mouth twice to total 400mg daily</description>
        </group>
        <group group_id="P3">
          <title>Arm 3- Healthy +Tocotrienol 400 mg</title>
          <description>Healthy patients to take Tocotrienol: 400 mg to take orally (two 200 mg capsules) two times a day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The healthy participants included: age 21â€“40 y, good health, nonsmoker, nonpregnant or nonbreastfeeding, and no recent (past 6 mo) or current use of supplements containing vitamin E. The surgical participants group included adipose, brain, cardiac muscle, and liver tissue of the surgical participants age 21 and older.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1- Surgical + Tocotrienol 200 mg</title>
          <description>Surgical Subjects will recieve either Tocotrienol: 200mg (two 100mg capsules) to take twice daily by mouth to make a total of 400mg per day</description>
        </group>
        <group group_id="B2">
          <title>Arm 2 - Surgical + Tocopherol 200 mg</title>
          <description>Surgical Subjects will recieve Tocopherol: 200mg (two 100mg capsules) to take twice daily by mouth to make a total of 400mg per day</description>
        </group>
        <group group_id="B3">
          <title>Arm 3- Healthy + Tocotrienol 200 mg</title>
          <description>Healthy Subjects will recieve either Tocotrienol: 200mg (two 100mg capsules) to take twice daily by mouth to make a total of 400mg per day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.37" spread="12.81"/>
                    <measurement group_id="B2" value="54" spread="11.56"/>
                    <measurement group_id="B3" value="30.24" spread="8.59"/>
                    <measurement group_id="B4" value="40.37" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Levels of TCT in the Tissues of &quot;Non-healthy&quot; Subjects and in the Tissue of &quot;Healthy&quot; Subjects Following Oral Supplementation (200 mg x 2 Per Day for 4-24 Weeks)</title>
        <time_frame>After at least 1 month of supplementation</time_frame>
        <population>Box plots were used to determine outliers defined as values . the 75th percentile plus 1.5 times the IQR or values , the 25th percentile minus 1.5 times the IQR (20). Outliers were identified and it was determined that laboratory procedural errors were the cause and thus removed from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Surgical, Adipose</title>
            <description>adipose aTE levels after supplementation (400mg/d)</description>
          </group>
          <group group_id="O2">
            <title>Arm 1: Surgical, Brain</title>
            <description>brain aTE levels after supplementation (400mg/d)</description>
          </group>
          <group group_id="O3">
            <title>Arm 1: Surgical, Heart</title>
            <description>heart aTE levels after supplementation (400mg/d)</description>
          </group>
          <group group_id="O4">
            <title>Arm 1: Surgical, Liver</title>
            <description>liver aTE levels after supplementation (400mg/d)</description>
          </group>
          <group group_id="O5">
            <title>Arm 2: Surgical, Adipose</title>
            <description>adipose aTCP levels after supplementation (400mg/d)</description>
          </group>
          <group group_id="O6">
            <title>Arm 2: Surgical, Brain</title>
            <description>brain aTCP levels after supplementation (400mg/d)</description>
          </group>
          <group group_id="O7">
            <title>Arm 2: Surgical, Heart</title>
            <description>heart aTCP levels after supplementation (400mg/d)</description>
          </group>
          <group group_id="O8">
            <title>Arm 2: Surgical, Liver</title>
            <description>liver aTCP levels after supplementation (400mg/d)</description>
          </group>
          <group group_id="O9">
            <title>Arm 3: Healthy, Blood, Week 0</title>
            <description>Baseline blood levels of aTE prior to supplementation</description>
          </group>
          <group group_id="O10">
            <title>Arm 3: Healthy, Blood, Week 6</title>
            <description>Blood levels of aTE after 6 weeks of supplementation (400mg/d)</description>
          </group>
          <group group_id="O11">
            <title>Arm 3: Healthy, Skin, Week 12</title>
            <description>skin levels of aTE after 12 weeks of supplementation (400mg/d)</description>
          </group>
          <group group_id="O12">
            <title>Arm 3: Healthy, Skin, Week 0</title>
            <description>baseline skin levels of aTE prior to supplementation</description>
          </group>
          <group group_id="O13">
            <title>Arm 3: Healthy, Blood, Week 12</title>
            <description>Blood levels of aTE after 12 weeks of supplementation (400mg/d)</description>
          </group>
        </group_list>
        <measure>
          <title>The Levels of TCT in the Tissues of &quot;Non-healthy&quot; Subjects and in the Tissue of &quot;Healthy&quot; Subjects Following Oral Supplementation (200 mg x 2 Per Day for 4-24 Weeks)</title>
          <population>Box plots were used to determine outliers defined as values . the 75th percentile plus 1.5 times the IQR or values , the 25th percentile minus 1.5 times the IQR (20). Outliers were identified and it was determined that laboratory procedural errors were the cause and thus removed from the analysis.</population>
          <units>nmol/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="16"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="16"/>
                <count group_id="O13" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.94" spread="6.9"/>
                    <measurement group_id="O2" value="1.29" spread="1.06"/>
                    <measurement group_id="O3" value="5.37" spread="4.28"/>
                    <measurement group_id="O4" value="0.42" spread="0.43"/>
                    <measurement group_id="O5" value="28.6" spread="20.7"/>
                    <measurement group_id="O6" value="50.5" spread="17.2"/>
                    <measurement group_id="O7" value="31.9" spread="20.0"/>
                    <measurement group_id="O8" value="64.3" spread="14.9"/>
                    <measurement group_id="O9" value="0.01" spread="0.02"/>
                    <measurement group_id="O10" value="1.9" spread="0.7"/>
                    <measurement group_id="O11" value="1.5" spread="1.8"/>
                    <measurement group_id="O12" value="2.5" spread="3.0"/>
                    <measurement group_id="O13" value="0.03" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>Surgery patients to take Tocotrienol capsules.: 200mg (two 100mg capsules)taken by mouth twice with foold to make a total of 400mg daily</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>Surgery patients to take Tocopherol capsules.: 200mg (two 100mg capsules)taken by mouth twice with foold to make a total of 400mg daily</description>
        </group>
        <group group_id="E3">
          <title>Arm 3</title>
          <description>Healthy patients to take either Tocotrienol or Tocopherol: 200mg (two 100mg capsules)taken by mouth twice with foold to make a total of 400mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Chandan K. Sen, PhD. Professor and Associate Dean</name_or_title>
      <organization>The Ohio State University Wexner Medical Center</organization>
      <phone>614-247-7658</phone>
      <email>chandan.sen@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

